Analyst Sees Keros Therapeutics As Subsequent Acceleron, Set For Main Biotech Progress – Keros Therapeutics (NASDAQ:KROS)

Oppenheimer initiated protection on Keros Therapeutics Inc KROS, a clinical-stage biopharmaceutical firm that develops and commercializes novel therapeutics for issues linked to dysfunctional signaling of the reworking progress factor-beta household of proteins.

Oppenheimer writes, “Keros is growing best-in-class therapeutics that regulate TGF-β signaling to deal with hematological and cardiopulmonary illnesses. We think about its pipeline one of many extra enticing in biotech right this moment, given its disease-modifying potential in indications with appreciable unmet want.”

Keros’ lead product candidate, KER-050 (elritercept), is being developed for low blood cell counts or cytopenias, together with anemia and thrombocytopenia, in sufferers with myelodysplastic syndromes (MDS) and myelofibrosis.

• The analyst sees elritercept because the potential most popular 2L therapy in MDS with sturdy responses and advantages.
• On the EHA replace, an total hematologic response was noticed in 56% of the mITT24 sufferers, with transfusion independence (TI)≥8 weeks achieved in 41%.

Oppenheimer initiates with an Outperform score and a worth goal of $102.

Keros’ second product candidate, KER-012 (cibotercept), is being developed for pulmonary arterial hypertension (PAH) and cardiovascular issues.

Keros’ third product candidate, KER-065, is being developed for weight problems and neuromuscular illnesses.

• KER-065 could be the darkish horse candidate in weight problems. Knowledge help inhibition of myostatin and activin A for maximal will increase in lean muscle mass and fats loss with clear security.

Within the close to time period, the principle elements driving worth for Keros are MDS and myelofibrosis. Wanting forward, there are vital progress alternatives in pulmonary arterial hypertension (PAH) and weight problems, which may yield substantial advantages over the following 12-18 months, the analyst writes.

Given administration’s monitor file in growing medicine that affect the TGF-β signaling pathway, these initiatives are seen as comparatively low-risk. Oppenheimer likens Keros to Acceleron, which achieved appreciable success and was acquired by Merck for $11.5 billion in 2021.

Worth Motion: KROS shares are down 0.82% at $46.10 finally test Tuesday.

Learn Subsequent:

Picture created utilizing synthetic intelligence through Midjourney.